Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Debt Ratio (2020 - 2025)

Historic Debt Ratio for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 0.02.

  • Insight Molecular Diagnostics' Debt Ratio rose 17485.35% to 0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02, marking a year-over-year increase of 17485.35%. This contributed to the annual value of 0.01 for FY2024, which is 7896.54% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Debt Ratio of 0.02 as of Q3 2025, which was up 17485.35% from 0.01 recorded in Q2 2025.
  • Insight Molecular Diagnostics' Debt Ratio's 5-year high stood at 0.07 during Q2 2021, with a 5-year trough of 0.0 in Q3 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' median Debt Ratio value was 0.01 (recorded in 2021), while the average stood at 0.01.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Debt Ratio tumbled by 9516.91% in 2022, and later skyrocketed by 273724.25% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Debt Ratio stood at 0.01 in 2021, then plummeted by 87.48% to 0.0 in 2022, then soared by 2737.24% to 0.03 in 2023, then tumbled by 78.97% to 0.01 in 2024, then surged by 269.8% to 0.02 in 2025.
  • Its Debt Ratio stands at 0.02 for Q3 2025, versus 0.01 for Q2 2025 and 0.01 for Q1 2025.